Diadem Biotherapeutics

Executive Summary

Diadem Biotherapeutics is a San Diego-based biotechnology company leveraging its proprietary DECOSTAR™ platform to engineer first-in-class extracellular vesicles (EVs) for the treatment of cancer, chronic inflammatory, and autoimmune diseases. Founded in 2018, the company addresses key biophysical challenges in immune receptor signaling, aiming to unlock novel therapeutic modalities with improved targeting and efficacy. While still in preclinical stages, Diadem's approach capitalizes on the growing interest in EV-based therapeutics, positioning it as an early innovator in a emerging field. The company remains privately held, with no disclosed funding rounds or valuation, but its science and platform could attract strategic partnerships or Series A financing. The lack of publicly available clinical or regulatory milestones limits visibility, making conviction moderate based on platform potential and team expertise.

Upcoming Catalysts (preview)

• Q4 2026Series A or Seed Extension Funding Announcement60% success
• Q2 2027Preclinical Proof-of-Concept Data (In Vivo) for Lead EV Program50% success
• Q3 2027Partnership or Collaboration with Larger Pharma (e.g., for EV Platform) – $5M+30% success